Behavioral Assessment Technology for Pharmacotherapy in Developmental Disabilities

  • Stephen R. Schroeder


The burgeoning field of behavioral assessment in behavioral medicine and in developmental disabilities requires that, for a meaningful discussion within a brief chapter, the topic must be restricted even further. We have chosen behavioral assessment of pharmacotherapy with persons who have developmental disabilities because it is currently a very visible and controversial topic, with a rich research literature. The plan of this paper is to review the necessary behavioral and pharmacological issues that need to be considered when evaluating or conducting research in this area. It is not an exhaustive review. More complete treatment of our approach to behavioral assessment in mental retardation can be found in Rojahn and Schroeder (1983) and to behavioral pharmacotherapy with developmental disabilities in Schroeder, Lewis, and Lipton (1983). We will recommend several other current topical reviews as the various topics are treated. Five textbooks are recommended: Gadow and Poling (1988), Gadow (1986), Gualtieri, Schroeder, & Keppel (1987); Hersen (1986), and Werry (1978).


Mental Retardation Psychotropic Drug Developmental Disability Uric Acid Level Behavioral Assessment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aman, M. G. (1984). Drugs and learning in mentally retarded persons. In G. D. Burrows & J. S. Werry (Eds.), Advances in human psychopharmacology (Vol 3, pp. 121–163 ). Greenwich, CT: J AI.Google Scholar
  2. Aman, M. G., & Singh, N. N. (1986). A critical appraisal of recent drug research in mental retardation: The Coldwater studies. Journal of Mental Deficiency Research, 30, 203–216.PubMedGoogle Scholar
  3. Aman, M. G., & White, A. J. (1986). Measures of drug change in mental retardation. In K. D. Gadow (Ed.), Advances in learning and behavioral disabilities (Vol. 5, pp. 157–202 ). Greenwich, CT: J AI.Google Scholar
  4. Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). The Aberrant Behavior Checklist: A behavior rating scale for measurement of treatment effects. American Journal of Mental Deficiency, 89, 485–491.PubMedGoogle Scholar
  5. Aman, M. G., Teehan, C. J., White, A. J., Turbott, S. H., & Vaithianathan, C. (1986). Haloperidol treatment with chronically medicated residents: Dose effects on clinical behavior and reinforcement contingencies. Manuscript submitted for publication.Google Scholar
  6. Baumeister, A. A., & Rollings, P. (1976). Self-injurious behavior. In N. R. Ellis (Ed.), International review of research in mental retardation (Vol. 9, pp. 1–33 ) New York: Academic.Google Scholar
  7. Baumeister, A. A., Frye, G. R., & Schroeder, S. R. (1984). Neurochemical correlates of self-injurious behavior. In J. A. Mulick & B. L. Mallory (Eds.), Transitions in mental retardation: Advocacy, technology and science. Norwood, NJ: Ablex.Google Scholar
  8. Breese, G. R., Baumeister, A. A., McCowan, T. J., Emerick, S., Frye, G. D., & Mueller, R. A. (1984). Neonatal-6-hydroxydopamine treatment: Model of susceptibility for self-mutilation in the Lesch-Nyhan syndrome. Pharmacology Biochemistry and Behavior, 21, 459–461.CrossRefGoogle Scholar
  9. Breese, G. R., Baumeister, A. A., McCown, T. J., Emerick, S., Frye, G. D., Crotty, K., & Mueller, R. A. (1985). Behavioral differences between neonatal- and adult-6-hydroxydopamine-treated rats to dopamine agonists: Relevance to neurological symptoms in clinical syndromes with reduced brain dopamine. Journal of Pharmacology and Experimental Therapeutics, 234, 447–455.PubMedGoogle Scholar
  10. Briant, R. H. (1978). An introduction to clinical pharmacology. In J. S. Werry (Ed.), Pediatric psychopharmacology (pp. 3–28 ). New York: Brunner/Mazel, 1978.Google Scholar
  11. Campbell, M., Anderson, L. T., Meier, M., Cohen, I. L., Small, A. M., Samit, C., & Sachar, E. J. (1978). A comparison of haloperidol and behavior therapy and their interaction in autistic children. Journal of the American Academy of Child Psychiatry, 17, 640–655.PubMedCrossRefGoogle Scholar
  12. Campbell, M., Anderson, L. T., Small, A. M., Perry, R., Green, W. H., & Caplan, R. (1982). The effects of haloperidol on learning and behavior in autistic children. Journal of Autism and Developmental Disorders, 12, 167–176.PubMedCrossRefGoogle Scholar
  13. Cataldo, M. F., & Harris, J. (1982). The biological basis for self-injury in the mentally retarded. Analysis and Intervention in Developmental Disabilities, 2, 21–39.CrossRefGoogle Scholar
  14. Chassan, J. B. (1979). Research design in clinical psychology and psychiatry. New York: Halstead.Google Scholar
  15. Christensen, D. E. (1975). Effects of combining methylphenidate and a classroom token system in modifying hyperactive behavior. American Journal of Mental Deficiency, 80, 266–276.PubMedGoogle Scholar
  16. Conners, C. K. (1969). A teacher rating scale for use in drug studies with children. American Journal of Psychiatry, 126, 152–156.Google Scholar
  17. Eaton, L. F., & Menolascino, F. J. (1982). Psychiatric disorders in the mentally retarded: Types, problems, and challenges. American Journal of Psychiatry, 139, 1297–1303.PubMedGoogle Scholar
  18. Gadow, K. D. (1982). Drug use in the public schools. In S. Breuning & A. Poling (Eds.), Drugs and mental retardation (pp. 330–350 ). Springfield, IL: Charles C Thomas.Google Scholar
  19. Gadow, K. D. (1986). Children on medication (Vols. 1 and 2 ). Waltham, MA: Little, Brown.Google Scholar
  20. Gadow, K. D., & Poling, A. G. (1988). Pharmacotherapy and mental retardation. Boston: Little, Brown.Google Scholar
  21. Gittleman-Klein, R., & Klein, D. (1976). Methylphenidate effects in learning disabilities: Psychometric changes. Archives of General Psychiatry, 33, 655–664.PubMedGoogle Scholar
  22. Goldstein, M., Anderson, L. T., Reuben, R., & Dancis, J. (1985). Self-mutilation in Lesch-Nyhan disease is caused by dopaminergic denervation. The Lancet, February 9, 338–339.CrossRefGoogle Scholar
  23. Gualtieri, C. T., & Hawk, B. (1980). Tardive dyskinesia and other drug-induced movement disorders among handicapped children and youth. Applied Research in Mental Retardation, 1, 55–69.PubMedCrossRefGoogle Scholar
  24. Gualtieri, C. T., Breese, G. R., Schroeder, S. R., & Keppel, J. M. ( 1986, March). Rational pharmacotherapy for self-injurious behavior: Testing the D-l model Paper presented at the 19th Gatlinburg Conference on Research and Theory in Mental Retardation and Developmental Disabilities. Gatlinburg, Tennessee.Google Scholar
  25. Gualtieri, C. T., Schroeder, S. R., & Keppel, J. M. (In press). Psychiatric treatment for mentally retarded people. Washington, DC: American Psychiatric Association Monographs.Google Scholar
  26. Helper, M., Wilcott, R., & Garfield, S. (1963). Effects of chlorpromazine on learning and related processes in emotionally disturbed children. Journal of Consulting Psychology, 27, 1–9.CrossRefGoogle Scholar
  27. Hersen, M. H. (1986). Pharmacological and behavioral treatment. New York: Wiley.Google Scholar
  28. Hicks, R. E., Gualtieri, C. T., Mayo, J. P., Schroeder, S. R., & Lipton, M. H. (1984). Methylphenidate and homeostasis: Drug effects on the cognitive performance of hyperactive children. In L. M. Bloomingdale (Ed.), Attention deficit disorder (Vol. 1, pp. 131–142 ). New York: Spectrum.Google Scholar
  29. Hollis, J. H. (1968). Chlorpromazine: Direct measurement of differential behavioral effect. Science, 159, 1487–1489.PubMedCrossRefGoogle Scholar
  30. Johnston, J. M., Wallen, A., Partin, J., Neu, E., Cade, R. F., Stein, G. H., Goldstein, M. K., Pennypacker, H. S., & Gfeller, E. (1983). Human operant laboratory measurement of the effects of chemical variables. Psychological Record, 33, 457–472.Google Scholar
  31. Kagan, J. (1966). Reflection-impulsivity: The generality and dynamics of conceptual tempo. Journal of Abnormal Psychology, 71, 17–24.PubMedCrossRefGoogle Scholar
  32. Kazdin, A. (1977). Artifact, bias, and complexity of assessment: The ABC’s of reliability. Journal of Applied Behavior Analysis, 10, 141–150.PubMedCrossRefGoogle Scholar
  33. Kinsbourne, M. (1985). Base-state dependency of stimulant effects on the cognitive performance of hyperactive children. In L. M. Bloomingdale (Ed.), Attention deficit disorder (Vol. 1, pp. 143–154 ). New York: Spectrum.Google Scholar
  34. Lesch, M., & Nyhan, W. L. (1964). A familial disorder of uric acid metabolism and central nervous system function. American Journal of Medicine, 36, 561–570.PubMedCrossRefGoogle Scholar
  35. Lewis, M. H., Steer, R. A., Favell, J., McGimsey, J., Clontz, L., Trivette, C., Jodry, W., Schroeder, S. R., Kanoy, R. C., & Mailman, R. B. (1986). Thioridazine and metabolite blood levels and effects on human stereotyped behavior. Psychopharmacology Bulletin, 22, 1040–1044.Google Scholar
  36. Lloyd, K. G., Hornykiewicz, O., Davidson, L., Shannak, K., Farley, I., Goldstein, M., Shibuya, M., Kelley, W., & Fox, I. H. (1981). Biochemical evidence of dysfunction of brain neurotransmitters in the Lesch-Nyhan syndrome. New England Journal of Medicine, 305, 1106–1111.PubMedCrossRefGoogle Scholar
  37. Lovaas, O. I., Freitag, G., Gold, V., & Kassorla, I. (1965). Experimental studies in childhood schizophrenia: Analysis of self-destructive behavior. Journal of Experimental Child Psychology, 2, 67–84.CrossRefGoogle Scholar
  38. Marholin, D., Touchette, P., & Stewart, R. M. (1979). Withdrawal of chronic chlorpromazine medication: An experimental analysis. Journal of Applied Behavior Analysis, 12, 159–171.PubMedCrossRefGoogle Scholar
  39. Nyhan, W. L., Johnson, H., Kaufman, I., Jones, K. (1980). Serotonergic approaches to modification of behavior in the Lesch-Nyhan syndrome. Applied Research in Mental Retardation, 1, 25–40.PubMedCrossRefGoogle Scholar
  40. Pardo, J. V., Creese, I., Burt, D. R., & Snyder, S. H. (1977). Ontogenesis of dopamine receptor binding in the corpus striatum of the rat. Brain Research, 125, 367–382.CrossRefGoogle Scholar
  41. Pfadt, A., & Tryon, W. W. (1983). Issues in the selection and use of mechanical transducers to directly measure motor activity in clinical settings. Applied Research in Mental Retardation, 4, 251–270.PubMedCrossRefGoogle Scholar
  42. Poling, A., & Breuning, S. E. (1983). Effects of methylphenidate on the fixed-ratio performance of mentally retarded children. Pharmacology, Biochemistry, and Behavior, 28, 541–544.CrossRefGoogle Scholar
  43. Poling, A., Picker, M., & Hall-Johnson, E. (1983). Human behavioral pharmacology. The Psychological Record, 33, 437–493.Google Scholar
  44. Rapoport, J. L., & Conners, K. C. (Eds.). (1985). Rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacology Bulletin, 21(4), 713–1124.Google Scholar
  45. Reatig, N. (Ed.). (1985). Pharmacotherapy and mental retardation workshop. Psychopharmacology Bulletin, 21(2), 258–333.Google Scholar
  46. Rie, D. R., & Rie, H. E. (1977). Recall, retention, and Ritalin. Journal of Clinical and Consulting Psychology, 47, 967–972.CrossRefGoogle Scholar
  47. Rojahn, J., & Schroeder, S. R. (1983). Behavioral assessment. In J. L. Matson & J. A. Mulick (Eds.), Handbook of mental retardation (pp. 227–244 ). New York: Pergamon.Google Scholar
  48. Schroeder, S. R. (1984). Neurochemical and behavioral interactions with stereotyped self-injurious behavior. In J. C. Griffin, M. T. Stark, D. E. Williams, B. K. Altmeyer, & H. K. Griffin (Eds.), Advances in the treatment of SIB (pp. 61–78 ). Austin: Texas Planning Council for Developmental Disabilities.Google Scholar
  49. Schroeder, S. R. (1985). Issues and future directions of pharmacotherapy in mental retardation. Psychopharmacology Bulletin, 21 (2), 323–326.PubMedGoogle Scholar
  50. Schroeder, S. R., & Gualtieri, C. T. (1985). Behavioral interactions induced by chronic neuroleptic therapy with persons with mental retardation, Psychopharmacology Bulletin, 21, 323–326.PubMedGoogle Scholar
  51. Schroeder, S. R., Lewis, M. H., & Lipton, M. A. (1983). Interactions of pharmacotherapy and behavior therapy among children with learning and behavioral disorders. In K. Gadow & I. Bailer (Eds.), Advances in learning and behavioral disabilities (Vol. 2, pp. 179–225 ). Greenwich, CT: JAI.Google Scholar
  52. Seeman, P. (1981). Brain dopamine receptors. Pharmacological Reviews, 32, 229–313.Google Scholar
  53. Sovner, R., & Hurley, A. D. (1983). Do the mentally retarded suffer from affective illness? Archives of General Psychiatry, 40, 61–67.PubMedGoogle Scholar
  54. Sprague, R., & Sleator, E. (1977). Methylphenidate in hyperkinetic children: Differences in dose effects on learning and social behavior. Science, 198, 1274–1276.PubMedCrossRefGoogle Scholar
  55. Sprague, R. L., & Werry, J. S. (1971). Methodology of psychopharmacology studies with the retarded. In N. R. Ellis (Ed.), International review of research in mental retardation (Vol. 5, pp. 147–219 ). New York: Academic.Google Scholar
  56. Sykes, D., Douglas, V., & Morgenstern, G. (1972). The effect of methylphenidate (Ritalin) or sustained attention in hyperactive children. Psychopharmacologia, 25, 262–274.PubMedCrossRefGoogle Scholar
  57. Walker, M. K. (1982). Stimulant drugs. In S. E. Breuning & A. D. Poling (Eds.), Drugs in mental retardation (pp. 235–267 ). Springfield, IL: Charles C Thomas.Google Scholar
  58. Walls, R. T., Werner, T. J. Bacon, A., & Zane, T. (1977). Behavior checklists. In J. D. Cone & R. P. Hawkins, (Eds.), Behavioral assessment: New directions in clinical psychology (pp. 77–146 ). New York: Brunner/Mazel.Google Scholar
  59. Werry, J. S. (Ed.). (1978). Pediatric psychopharmacology. New York: Brunner/Mazel.Google Scholar
  60. Whalen, C. K., & Henker, B. (1976). Psychostimulants and children: A review and analysis. Psychological Bulletin, 83, 1113–1130.PubMedCrossRefGoogle Scholar
  61. White, T. J., & Aman, M. G. (1985). Pimozide treatment in disruptive severely retarded patients. Australian-New Zealand Journal of Psychiatry, 19, 92–94.CrossRefGoogle Scholar
  62. Wysocki, T., Fuqua, W., Davis, V., & Breuning, S. E. (1981). Effects of thioridazine (Mellaril) on titrating delayed matching-to-sample performance of mentally retarded adults. American Journal of Mental Deficiency, 85, 539–547.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1988

Authors and Affiliations

  • Stephen R. Schroeder
    • 1
  1. 1.The Nisonger CenterOhio State UniversityColumbusUSA

Personalised recommendations